Cargando…

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial

YKL-40 is a glycoprotein with pro-angiogenic functions. We hypothesized that patients with newly diagnosed glioblastoma and low baseline plasma YKL-40 levels derive greater benefit from first-line bevacizumab. Plasma samples were collected from 563 patients in the randomized, phase 3 AVAglio trial w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boisen, Mogens K., Holst, Camilla B., Consalvo, Nicola, Chinot, Olivier L., Johansen, Julia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805511/ https://www.ncbi.nlm.nih.gov/pubmed/29467925 http://dx.doi.org/10.18632/oncotarget.22886

Ejemplares similares

Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study
por: Jiguet-Jiglaire, Carine, et al.
Publicado: (2022)

Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2020)

Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021)

Plasma YKL-40 is associated with prognosis in patients with metastatic pancreatic cancer receiving immune checkpoint inhibitors in combination with radiotherapy
por: Johansen, Astrid Z., et al.
Publicado: (2023)

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Serum YKL-40 and colorectal cancer
por: Cintin, C, et al.
Publicado: (1999)

Vascular heterogeneity and targeting: the role of YKL-40 in glioblastoma vascularization
por: Shao, Rong, et al.
Publicado: (2015)

YKL-40 tissue expression and plasma levels in patients with ovarian cancer
por: Høgdall, Estrid VS, et al.
Publicado: (2009)

Plasma YKL-40: A BMI-Independent Marker of Type 2 Diabetes
por: Nielsen, Anders R., et al.
Publicado: (2008)

Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma
por: Iwamoto, Fabio M., et al.
Publicado: (2014)

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease
por: Holmgaard, Dennis B, et al.
Publicado: (2013)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

YKL-40 - an emerging biomarker in cardiovascular disease and diabetes
por: Rathcke, Camilla N, et al.
Publicado: (2009)

Transient Changes in Serum CEA, CA19-9, CRP, YKL-40, and IL-6 during Adjuvant Chemotherapy and Survival of Patients with Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer
por: Lehtomäki, Kaisa, et al.
Publicado: (2021)

TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells
por: Pinet, Sandra, et al.
Publicado: (2016)

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014)

Serum YKL-40 Levels Are Associated with the Atherogenic Index of Plasma in Children
por: Kwon, Yoowon, et al.
Publicado: (2020)

The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
por: Chen, Wei-jun, et al.
Publicado: (2020)

YKL-40 correlates with the phenotype of asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

Prognosis and Reclassification by YKL‐40 in Stable Coronary Artery Disease
por: Schroder, Jakob, et al.
Publicado: (2020)

Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves’ disease
por: Chen, Yi-Ding, et al.
Publicado: (2023)

Pretreatment Plasma IL-6 and YKL-40 and Overall Survival after Surgery for Metastatic Bone Disease of the Extremities
por: Sørensen, Michala Skovlund, et al.
Publicado: (2021)

Usefulness of Plasma YKL-40 in Management of Community-Acquired Pneumonia Severity in Patients
por: Wang, Hsiang-Ling, et al.
Publicado: (2013)

Plasma YKL-40 and NGAL are useful in distinguishing ACO from asthma and COPD
por: Wang, Jing, et al.
Publicado: (2018)

YKL-40 Protein Correlates with the Phenotype of Asthma
por: Specjalski, Krzysztof, et al.
Publicado: (2015)

YKL-40 in the brain and cerebrospinal fluid of neurodegenerative dementias
por: Llorens, Franc, et al.
Publicado: (2017)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

Cancer risk by combined levels of YKL-40 and C-reactive protein in the general population
por: Allin, K H, et al.
Publicado: (2012)

The inflammatory biomarker YKL-40 decreases stepwise after exercise stress test
por: Dam Mygind, Naja, et al.
Publicado: (2016)

Functional analysis of the short splicing variant encoded by CHI3L1/YKL-40 in glioblastoma
por: Shi, Mengqi, et al.
Publicado: (2022)

Relationship between plasma YKL-40 levels and endothelial dysfunction in chronic kidney disease
por: KESKİN, Gül Sema, et al.
Publicado: (2019)

Elevated plasma YKL-40 level is found in the dogs with cancer and is related to poor prognosis
por: Cheng, Kai-Chung, et al.
Publicado: (2019)

Plasma levels of YKL-40 as a prognostic factor in childhood acute lymphoblastic leukemia
por: Rivas-Alarcón, Alinne Ayulieth, et al.
Publicado: (2021)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?
por: Schultz, Nicolai A., et al.
Publicado: (2010)

Serum YKL-40 Levels in Patients with Gastric Cancer
por: Itik, Veyis, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_191v7pvvdo93iu9k6ogl73jih1